Drug intelligence / Profile preview

Anyanda ALK5 inhibitor series (CN122036718A)

Development stage: Unknown
Lead developer: Anyanda Pharmaceutical Technology
Modality: Small Molecules

Overview

Anyanda ALK5 inhibitor series (CN122036718A): sourced facts only. name: "This invention discloses an ALK5 inhibitor, its preparation method, and its application." [1] target: "Its IC50 value for inhibiting ALK5 activity is 0.879-5.23 nmol/L." [1] developer: "Anyanda Pharmaceutical Technology Guangzhou Co ltd" [1] stage: "has broad potential for development into a treatment for gastrointestinal fibrosis and gastrointestinal tumors," [1] modality: "The ALK5 inhibitor is a compound represented by Formula I." [1]

Targets

TGFBR1

Beyond the preview

Go deeper on Anyanda ALK5 inhibitor series (CN122036718A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anyanda ALK5 inhibitor series (CN122036718A).